AxoGen to Present at Lazard Capital Markets Medical Technology Conference

ALACHUA, Fla.--(BUSINESS WIRE)--AxoGen, Inc. (OTCBB: AXGN) a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will be presenting at the Lazard Capital Markets 5^th Annual Medical Technology Snowbird Conference.

The event is being held from February 27 - March 1, 2013 at The Cliff Hotel, Snowbird Ski and Summer Resort in Snowbird, Utah. The conference format consists of a full day of one-on-one meetings and will not be webcast.

Institutional investors that wish to request a meeting with AxoGen should contact Lazard Capital Markets or AxoGen Investor Relations.

About AxoGen, Inc.

AxoGen (OTCBB: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at www.axogeninc.com.